Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Getting past PTSD

How Neurovation’s GRIA1 programs could improve PTSD diagnosis and treatment

Neurovation Labs Inc. is developing a GRIA1-targeting tracer and a small molecule therapy that could provide an objective diagnosis of PTSD and treat the underlying disease instead of just its symptoms.

Post-traumatic stress disorder (PTSD) is diagnosed with a symptom checklist that is typically self-reported and therefore not objective.

Approved treatments include behavioral psychotherapy and the generic serotonin reuptake inhibitor (SSRI)

Read the full 607 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE